Key Stats for IQVIA Holdings Stock
- Price Change: -0.6%
- Current Price: $203
- Advanced Model Target: $303
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Shares of IQVIA Holdings Inc. (IQV) dipped 0.6% to close at $203 on Wednesday as the market digested the company’s latest strategic updates from the UBS Global Healthcare Conference.
The company recently reported Q3 financial results at the high end of guidance, demonstrating resilience in a challenging clinical trial environment.
CEO Ari Bousbib emphasized the company’s long-term pivot to “AI Agentification”, a strategy designed to automate complex clinical data processes.
Analysts at Goldman Sachs maintain a Buy rating with a target of $261, citing the company’s proprietary data moat.
Meanwhile, Baird reaffirmed an Outperform rating, highlighting the firm’s ability to expand margins by 30 basis points annually.
Sector peers like Veeva Systems (NYSE:VEEV) and Icon PLC (NASDAQ:ICLR) are also investing heavily in AI to streamline drug development timelines.
Despite the flat performance, the company continues to generate strong free cash flow, with management confirming that its cost reduction initiatives are offsetting business mix headwinds.
See analysts’ growth forecasts and price targets for IQVIA Holdings stock (It’s free!) >>>
Is IQVIA Holdings Undervalued Today?
During the conference, CEO Ari Bousbib provided deep insights into the structural advantages of their AI strategy.
He stated: “AI agents are only as good as the ingredients they’re trained on… And only we have those ingredients in the industry.”
Regarding the financial outlook for 2026 and beyond, management reiterated their confidence in delivering consistent profitability growth.
He noted: “That flat to 30 bps of margin expansion on average per year going forward still stands… supported long term by the AI agentification activities.”
The leadership team believes that as biopharma R&D spend stabilizes, IQVIA’s unique data assets will become even more critical for drug developers.
Read the full IQVIA Transcript on TIKR to see the AI roadmap >>>
According to TIKR’s Advanced Valuation Model, the current market price of $203 offers a substantial discount for a dominant player in healthcare data.
- Target Price: $303
- Current Price: $203
- Potential Upside: +49.6%
The investment case for IQVIA centers on its “unreplicable” data moat and its integration of AI into the clinical trial lifecycle.
If IQVIA successfully executes its AI roadmap and maintains its pricing power, the gap to $303 could close rapidly in 2026.
Conclusion: The data giant is poised for an AI-led breakout. With a 49.6% upside potential and a model pointing to $303, IQVIA stock offers a rare mix of defensive healthcare exposure and aggressive AI growth upside through 2026.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
How Much Upside Does IQVIA Holdings Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
